The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
The launch of the first oral GLP-1 weight-loss drug, Wegovy pill, is sparking renewed interest among employees wary of injections. But as demand surges, employers face tough choices on coverage amid high costs and side effects. This guide outlines 4 key facts from industry experts to inform your benefits strategy.
A new Cambridge study reveals that after stopping GLP-1 drugs like Ozempic and Wegovy, patients regain nearly 60% of lost weight within a year, with appetite returning rapidly. Researchers modeled long-term trends showing about 75% regain over time, emphasizing the need for lifestyle support. This comprehensive guide breaks down the findings and what they mean for patients.
New research reveals GLP-1 medications like Ozempic may significantly elevate risks of bone disorders and tendon injuries. Analyzing nearly 150,000 patients, the study found 30% higher osteoporosis rates and 50% increased tendon rupture risks over five years. Experts urge bone density monitoring amid these findings.
A spectacular backfire in Novo Nordisk's head-to-head trial against Eli Lilly's Mounjaro has widened the gap in the weight loss drug race, yet Ireland stands to gain from both giants. With billions in investments, thousands of jobs, and massive tax revenues, the Republic is placing an each-way bet on Wegovy and Mounjaro. This economic tie underscores pharma's pivotal role in Ireland's prosperity.
A new analysis shows semaglutide, the key ingredient in Ozempic and Wegovy, can be produced for just $3 per month. As patents expire in countries like Brazil, China, and India, generics could dramatically boost access to obesity and diabetes treatments worldwide. This development offers hope amid rising global rates of these conditions.
This week's science news uncovers surprising benefits of Ozempic for joint health beyond weight loss, reveals why superagers stay sharp with more new brain neurons, and highlights food quality over diet type for heart protection. From cholesterol-lowering oatmeal diets to a universal nasal vaccine, these findings offer fresh hope for metabolic and cognitive health.
Oprah Winfrey turned heads at Paris Fashion Week with a noticeably slimmer figure, igniting Ozempic speculation across social media. While the 72-year-old host hasn't confirmed using the drug, her recent podcast revelations about GLP-1 medications have fueled the conversation. Dive into the details of her chic appearance and the science of these popular injectables.
Doctors publicly tout GLP-1 drugs like Ozempic for weight loss, but privately warn patients may need them lifelong. A systematic review of 48 studies reveals up to 60% weight regain after stopping. Here's how to use Ozempic as a kickstart and make weight loss permanent with lifestyle changes.
While AI hype focuses on drug discovery, Eli Lilly has quietly used it to supercharge manufacturing of its blockbuster GLP-1s, Zepbound and Mounjaro. This led to record production volumes that avoided FDA shortages and fueled massive revenue growth. Here's how they did it with digital twins and defect detection tech.
